Anavex Advances Drug Candidates for Treatment of Epilepsy

Results in epilepsy animal models demonstrate that ANAVEX 2-73 and its active metabolite ANAVEX 19-144 have potent anticonvulsant, anti-amnesic and neuroprotective properties Geneva, Switzerland — December 6, 2007 — Anavex Life Sciences Corp. (“ANAVEX”) (OTCBB: AVXL) today announced promising developments with ANAVEX 2-73 and ANAVEX 19-144, the company’s lead drug candidates to treat epilepsy. During…

Anavex Life Sciences Engages Primoris Group to Provide Investor Relations Services

Geneva, Switzerland — November 2, 2007 — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (OTCBB: AVXL) is pleased to announce that it has engaged Primoris Group Inc. to provide investor relations services to the Company.  Primoris Group is a full-service investor relations firm based in Toronto,Canada.Primoris Group will implement a communications program to support…

Annual General Meeting of the Shareholders of Anavex Life Sciences Corp.

The Annual General Meeting of Anavex Life Sciences Corp. shareholders was held on May 25, 2007 in Geneva, Switzerland Geneva, Switzerland — June 5, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB:AVXL) a biopharmaceutical company, announced the results of its recently held Annual General Meeting. At the Annual General Meeting shareholders  elected  Dr. Panos Kontzalis, Mr.…

Preclinical Data of ANAVEX 1-41 and ANAVEX 2-73 Show Highly Potent Anti-Amnesic and Neuroprotective Activity Against Amyloid Beta (25-35) Peptide Toxicity in Alzheimer’s Disease (AD) Animal Models

Data on Anavex’s sigma-ligands ANAVEX 1-41 and ANAVEX 2-73 was presented in a poster at the 8e Colloque de la Societe des Neurosciences Meeting being held in Montpellier, France (Abstract D.30) May 22, 2007 Geneva, Switzerland — May 23, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB: AVXL) a biopharmaceutical company, today announced that…

Dr. Jean Jacques Bourguignon Joins Anavex Life Sciences Corp. Scientific Team

Geneva, Switzerland — April 16, 2007 — Anavex Life Sciences Corp. (the “Company”) (OTCBB: AVXL) a biopharmaceutical company, today announced that Jean Jacques Bourguignon, Ph.D., has joined the company’s scientific team and has been appointed a member of the Scientific Committee. Dr. Bourguignon brings 30 years of solid experience in the field of medicinal chemistry…